Cerivastatin (sodium)

Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect[1][2].

Product Specifications

CAS Number

[143201-11-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Ferroptosis; HMG-CoA Reductase (HMGCR)

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/cerivastatin-sodium.html

Purity

99.89

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C([O-])C[C@H](O)C[C@H](O)/C=C/C1=C(C2=CC=C(F)C=C2)C(COC)=C(C(C)C)N=C1C(C)C.[Na+]

Molecular Formula

C26H33FNNaO5

Molecular Weight

481.53

Precautions

H302, H315, H319, H335

References & Citations

[1]Denoyelle C, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001 Aug;22 (8) :1139-48.|[2]Stein E, et al. Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia. J Cardiovasc Pharmacol Ther. 1997 Jan;2 (1) :7-16.|[3]Furberg CD, et al. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2 (5) :205-207.